The Food and Drug Administration has accepted Lannett’s abbreviated new drug application for fluticasone propionate and salmeterol inhalation powder in three strengths — a generic of GlaxoSmithKline's ...
Lannett has submitted an ANDA to the Food and Drug Administration for its strategic partner, Respirant's fluticasone propionate and salmeterol inhalation powder (100/50 mcg, 250/50 mcg and 500/50 mcg) ...
LONDON, April 20, 2021 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces that it has resumed the launch of its generic version of GlaxoSmithKline's ...
LONDON, June 10 (Reuters) - Generic companies hoping to market a cheap copy of GlaxoSmithKline's best-selling inhaled lung drug Advair might have wait until 2012 before winning a green light from ...
PHILADELPHIA, June 1, 2021 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced the U.S. Food and Drug Administration (FDA) has accepted the Abbreviated New Drug Application (ANDA) for ...
LONDON, March 29 (Reuters) - GlaxoSmithKline shares gained on Wednesday as lack of news about U.S. approval of a generic copy of its blockbuster inhaled lung drug Advair buoyed speculation that a ...
PHILADELPHIA, April 1, 2021 /PRNewswire/ — Lannett Company, Inc. (NYSE: LCI) today announced the submission of an Abbreviated New Drug Application (ANDA) for Fluticasone propionate and Salmeterol ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results